Famotidine for Coronavirus

Phase 2

Waitlist Available

Led By Tobias Janowitz, MD, PhD

Research Sponsored by Northwell Health

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up day 7, 14, and 28.

Summary

The overall objective of this study is to evaluate the clinical efficacy of oral famotidine in symptomatic non-hospitalized patients with confirmed COVID-19. This study is expected to enroll up to 84 patients with mild to moderate symptoms divided into each of the two study arms. Clinical outcomes of the two treatment arms will be compared. This study will be conducted virtually/remotely.

Eligible Conditions

Coronavirus

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ day 7, 14, and 28.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~day 7, 14, and 28.

This trial's timeline: 3 weeks for screening, Varies for treatment, and day 7, 14, and 28. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Secondary study objectives

Assessment of Serious Adverse Events

Change in CRP

Change in ferritin

+8 more

Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: FamotidineActive Control1 Intervention

Participants in this study arm will receive standard of care and prescribed famotidine at 80mg TID for a maximum of 14 days, or until hospital admission.

Group II: PlaceboPlacebo Group1 Intervention

Participants in this study arm will receive standard of care and placebo for a maximum of 14 days.

Do I qualify?Apply below to find out